1. Introduction {#sec1}
===============

Mesenchymal stem cells (MSCs) can spontaneously proliferate and differentiate varieties of cell types, including osteoblasts, chondrocytes, adipoblasts, skeletal myocytes, and tenocyte \[[@B1], [@B2]\]. Furthermore, previous studies have shown that MSCs have unique immunomodulatory properties and potent immunosuppressive activities because they inhibit alloreactive T cell responses \[[@B2]--[@B4]\]. Instead, MSCs have been demonstrated to inhibit the function of immune cells, such as *αβ* T cells \[[@B3], [@B5], [@B6]\], NK cells \[[@B3], [@B7]--[@B9]\], macrophage \[[@B3]\], and dendritic cells (DCs) \[[@B2], [@B3], [@B10]\]. In addition, MSCs can enhance regulatory T cell responses and help tissue repairs \[[@B11]\]. Because of unique features, they have been widely investigated as a new therapy for graft versus host disease (GvHD) \[[@B12], [@B13]\], myocardial infarction, stroke, lupus, arthritis, Crohn\'s disease, acute lung injury, chronic obstructive pulmonary disease (COPD), cirrhosis, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and diabetes \[[@B13]\]. Among all sources of MSCs \[[@B2]\], umbilical cord derived MSCs (UC-MSCs) offer other feasible candidates for MSC-based therapies because of their abundant resources, noninvasive acquiring, low immunogenicity, and great capacity of ex vivo expansion \[[@B2], [@B14]\].

*γδ* T cells have unique innate and adaptive immunity features and account for approximately 1%--5% of circulating T cells \[[@B15], [@B16]\]. *γδ* T cells can respond to exotic factors \[[@B17], [@B18]\] and periphery blood V*γ*9V*δ*2 T cells, and the largest subset of *γδ* T cells can be activated by small nonpeptide phosphoantigens such as isopentenyl pyrophosphate (IPP) and pamidronate (PAM) \[[@B19], [@B20]\] in an HLA-unrestricted manner \[[@B16], [@B21]\]. Functionally, V*γ*9V*δ*2 T cells play an important role in host defense, especially in homeostasis and surveillance \[[@B21]\]. Previous studies have shown that V*γ*9V*δ*2 T cells regulate the process of innate immunity \[[@B22]\], immune responses against infection \[[@B17], [@B23]\], cancer \[[@B15], [@B22], [@B24]\], and autoimmune disease \[[@B25]\]. Both V*γ*9V*δ*2 T cells and MSCs play regulating roles in GvHD and some autoimmune diseases \[[@B13], [@B25], [@B26]\]; however, how V*γ*9V*δ*2 T cells respond to allogeneic UC-MSCs has not been clarified.

In this study, we isolated and expanded UC-MSCs as well as peripheral blood mononuclear cells (PBMCs) from healthy donors and examined the regulatory effect of allogeneic UC-MSCs on the proliferation, cytokine production, and cytotoxicity of V*γ*9V*δ*2 T cells in vitro. Our findings indicated that UC-MSCs inhibited the proliferation, cytokine production, and cytotoxicity of V*γ*9V*δ*2 T cells in vitro. Cell contact and apoptosis of V*γ*9V*δ*2 T cells were not necessary for the inhibition. Fas-L and TRAIL were involved in the regulation. We discussed the implications of our findings.

2. Materials and Methods {#sec2}
========================

2.1. Preparation of UC-MSCs {#sec2.1}
---------------------------

The experimental protocol was approved by the Institutional Review Board of Sichuan University. UC-MSCs were isolated from human umbilical cords, as described previously \[[@B27]\]. UC-MSCs were cultured in a 75-cm² flask in *α*-MEM medium (Hyclone, Chengdu, China) containing 15% heat inactivated fetal bovine serum (FBS, BioWest, South America), 100 units/mL of penicillin, and 100 *μ*g/mL of streptomycin at 37°C in 5% CO~2~ incubator. When the cells reached 80% confluency, UC-MSCs were digested with 0.25% trypsin and harvested for subculture or irradiation procession. The expanded UC-MSCs were characterized for their abilities to self-renew and differentiate multiple lineages of cells (data not shown). UC-MSCs were irradiated by X-ray (30 Gy) on Precision X-ray, (X-RAD 320), and cocultured with PBMCs or V*γ*9V*δ*2 T cells.

2.2. Preparation of PBMCS and V*γ*9V*δ*2 T Cells {#sec2.2}
------------------------------------------------

Human peripheral blood samples were obtained from healthy donors and PBMCs were isolated by Ficoll-Hypaque (Pharmacia, Piscataway, NJ, USA) density gradient centrifugation, as previously described \[[@B23]\]. The isolated PBMCs were cultured in RPMI-1640 medium supplemented with 10% FBS, 100 units/mL of penicillin, 100 *μ*g/mL of streptomycin, 2 *μ*g/mL of pamidronate disodium (PAM), and 100 IU/mL of human recombinant IL-2 (Invitrogen, Carlsbad, CA, USA). The cells were exposed to freshly prepared PAM and IL-2 medium and then cultured with freshly prepared medium containing IL-2 every three days up to two weeks. The contained V*γ*9V*δ*2 T cells were purified by negative selection using a TCR V*γ*9V*δ*2 T-cell isolation kit, according to the manufacturer\'s instruction (Miltenyi Biotec, Bergisch Gladbach, Germany). Check the V*γ*9V*δ*2 T cells by flow cytometry. V*γ*9V*δ*2 T cells were gated on CD3+TCR*γδ*+ in lymphocytes.

2.3. PBMCs/V*γ*9V*δ*2 T Cells Cocultured with UC-MSCs {#sec2.3}
-----------------------------------------------------

PBMCs were cocultured with UC-MSCs in 10% FBS RPMI 1640 medium containing PAM and IL-2 with or without transwell system. PBMCs (1.5∗10^6^/well) were cocultured with 30 Gy-irradiated UC-MSCs at cell ratios of 5 : 1, 20 : 1, 80 : 1, or 320 : 1 for 48 hours to 14 days. In transwell system, PBMCs/V*γ*9V*δ*2 T cells were cultured at the top chamber of 24-well transwell plates (0.4 mm pore; Millipore, Bedford, MA, USA) and 30 Gy-irradiated UC-MSCs were cultured at the bottom chamber of the plates.

2.4. Proliferation Assay {#sec2.4}
------------------------

The isolated PBMCs (1.0∗10^6^/mL) were labeled with 1 *μ*M 5,6-carboxyfluorescein diacetate N-succinimidyl ester (CFSE, Dojindo, Kumamoto, Japan) for 15 minutes. After being washed, the labeled PBMCs were cocultured with UC-MSCs in triplicate at the cell ratios of 5 : 1, 20 : 1, 80 : 1, and 320 : 1 for 14 days with PAM and IL-2. The cells were exposed to freshly prepared medium every three days. The cells were stained PE-anti-TCR*γδ* and APC-cy7-anti-CD3 (BD Biosciences, San Jose, USA) and the frequency of V*γ*9V*δ*2 T cell proliferation was determined by flow cytometry on a BECKMAN, FC 500, followed by analyzing the data with FlowJo software (Tree Star, Inc., Ashland, OR, USA).

Furthermore, the CFSE-labeled PBMCs (1.5∗10^6^/well) at the top chamber of 24-well transwell plates (0.4 mm pore; Millipore, Bedford, MA, USA) were cocultured with 30 Gy-irradiated UC-MSCs at the bottom chamber of the plates at the cell ratios of 5 : 1, 20 : 1, or 80 : 1 for 14 days with PAM and IL-2. PBMCs alone at the top chamber served as controls. The PBMCs were stained with PE-anti-TCR*γδ* and APC-cy7-anti-CD3 to determine the proliferation of V*γ*9V*δ*2 T cells.

2.5. Cytokine Assay {#sec2.5}
-------------------

Freshly isolated PBMCs were stimulated with PAM and IL-2 for 12 days and the cells were cocultured with, or without, allogeneic irradiated UC-MSCs at cell ratios of 5 : 1 or 80 : 1 for 48 hours. During the last 4-hour culture, the cells were treated with Brefeldin A. Subsequently, the cells were harvested, stained with APC-cy7-anti-CD3 and APC-anti-TCR*γδ*, fixed, permeabilized, and intracellularly stained with FITC-anti-IFN*γ*, PE-anti-TNF*α*, PE-anti-IL-10, PE-anti-perforin, or FITC-anti-granzyme B (BD Biosciences) to examine the frequency of cytokine-expressing V*γ*9V*δ*2 T cells, respectively.

2.6. Cytotoxicity Assay {#sec2.6}
-----------------------

Human adenocarcinomic alveolar basal epithelial A549 cells provided by the laboratory were cultured in 10% FBS RPMI 1640 medium. Furthermore, A549 cells were cultured overnight and, after being washed with phosphate-buffered saline (PBS), the cells were infected with influenza virus H1N1 (A/PR/8/34) \[[@B27]\] at a multiplicity of infection (MOI) of 2 for 1 hour, followed by washing out free virus with PBS.

Freshly isolated PBMCs were stimulated with PAM and IL-2 for 12 days and were cocultured with allogeneic irradiated UC-MSCs at cell ratios of 5 : 1 or 80 : 1 for 60 hours. The contained V*γ*9V*δ*2 T cells were purified by negative selection, as described above. The purified V*γ*9V*δ*2 T cells (effector) were cocultured in triplicate with influenza virus- (H1N1-) infected A549 cells (target) at an effector-to-target (E/T) ratio of 10 : 1 for 5 hours. Subsequently, the cells were stained with APC-cy7-anti-CD3 and 7AAD (BD Biosciences) and the percentages of dead A549 cells in total CD3-A549 cells were determined by flow cytometry.

2.7. Apoptosis Assay {#sec2.7}
--------------------

Freshly isolated PBMCs were stimulated with PAM and IL-2 in the presence or absence of irradiated UC-MSCs at the cell ratio of 5 : 1 or 80 : 1 for 14 days. The cells were harvested and stained with APC-cy7-anti-CD3, APC-anti-TCRV*γ*9V*δ*2, and PE-anti-Fas-L or PE-anti-TRAIL. The frequency of Fas-L+ or TRIAL+ V*γ*9V*δ*2 T cells was determined by flow cytometry. In addition, some cells were stained with APC-cy7-anti-CD3, APC-anti-TCR*γδ*, FITC-Annexin-V, and 7-AAD to determine the frequency of apoptotic V*γ*9V*δ*2 T cells.

2.8. Statistical Analysis {#sec2.8}
-------------------------

Data are representative FACS charts or histograms or expressed as the mean ± SEM. The difference among groups was analyzed by ANOVA and post hoc*t*-test using GraphPad Prism software (version 5). A *P* value of \<0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. UC-MSCs Inhibit the Proliferation of Allogeneic V*γ*9V*δ*2 T Cells {#sec3.1}
-----------------------------------------------------------------------

We characterized the frequency of peripheral blood V*γ*9V*δ*2 T cells by flow cytometry analysis and found that peripheral blood V*γ*9V*δ*2 T cells accounted for 3%--8% of T cells (data not shown). Following stimulation with PAM and IL-2 for 14 days, the percentages of V*γ*9V*δ*2 T cells reached 40%--90% of cultured T cells. To determine the effect of UC-MSCs on the allogeneic V*γ*9V*δ*2 T cell proliferation, PBMCs were isolated from healthy donors and labeled with CFSE. The labeled PBMCs were stimulated with PAM and IL-2 in the presence or absence of different numbers of irradiated UC-MSCs for 14 days. Subsequently, the cells were stained with PE-anti-TCR*γδ* and APC-cy7-anti-CD3 and the percentages of V*γ*9V*δ*2 T cells were determined by flow cytometry ([Figure 1(a)](#fig1){ref-type="fig"}). Quantitative analysis indicated that while near 60% of V*γ*9V*δ*2 T cells underwent proliferation in the absence of UC-MSCs. The percentages of V*γ*9V*δ*2 T cells in the presence of 320 : 1 UC-MSCs were significantly reduced by 28.3% (*P* \< 0.01, [Figure 1(c)](#fig1){ref-type="fig"}). The percentages of V*γ*9V*δ*2 T cells in the presence of greater numbers of UC-MSCs were further reduced by 67.2%, 81.7%, and 93.0% for 80 : 1, 20 : 1, and 5 : 1, respectively. Besides, the incomplete dilution of CFSE of V*γ*9V*δ*2 T cells into cell progenies showed the suppression of UC-MSCs on V*γ*9V*δ*2 T cells proliferation ([Figure 1(b)](#fig1){ref-type="fig"}). Hence, UC-MSCs inhibited PAM-stimulated V*γ*9V*δ*2 T cell proliferation in a dose-dependent manner in vitro.

To understand the importance of cell-to-cell contact in inhibition of UC-MSCs on V*γ*9V*δ*2 T cell proliferation, the CFSE-labeled PBMCs (1.5∗10^6^/well) in the top chamber of 24-well transwell plates were cocultured with irradiated UC-MSCs in the bottom chamber of the plates in triplicate at the cell ratios of 5 : 1, 20 : 1, or 80 : 1 for 14 days. PBMCs alone in the top chamber served as controls. Subsequently, the PBMCs were stained with PE-anti-TCR*γδ* to determine the frequency of V*γ*9V*δ*2 T cells by flow cytometry. As shown in [Figure 2(a)](#fig2){ref-type="fig"}, UC-MSCs inhibited the frequency of allogeneic V*γ*9V*δ*2 T cells when both types of cells were cocultured together. Similarly, UC-MSCs also inhibited the proliferation of allogeneic V*γ*9V*δ*2 T cells when both types of cells were separately cultured in the top and bottom chambers and there was no significant difference in the inhibitory effects between these two different tests ([Figure 2(b)](#fig2){ref-type="fig"}). Together, these data clearly indicated that UC-MSCs inhibited the proliferation of allogeneic V*γ*9V*δ*2 T cells in a cell-to-cell contact independent manner.

3.2. UC-MSCs Regulate Cytokine Production by V*γ*9V*δ*2 T Cells {#sec3.2}
---------------------------------------------------------------

Activated V*γ*9V*δ*2 T cells can express different cytokines and cytotoxic enzymes. To determine the effect of UC-MSCs on the expression of cytokines and functional enzymes, the isolated PBMCs were stimulated with PAM and IL-2 for 12 days and the cells were cocultured with, or without, irradiated UC-MSCs in triplicate at cell ratios of 5 : 1 or 80 : 1 for 48 hours (with Brefeldin A for the last 4 hours). Subsequently, the cells were harvested, stained with APC-cy7-anti-CD3 and APC-anti-TCR*γδ*, fixed, permeabilized, and intracellularly stained with FITC-anti-IFN*γ*, PE-anti-TNF*α*, PE-anti-IL-10, PE-anti-perforin, or FITC-anti-granzyme B. The percentages of TNF*α*+, IFN*γ*+, perforin+, granzyme B+, or IL-10+ V*γ*9V*δ*2 T cells were determined by flow cytometry. After being gated on CD3+TCR*γδ*+ cells, there was no significant difference in the frequency of TNF*α*+, perforin+, or IL-10+ V*γ*9V*δ*2 T cells in total V*γ*9V*δ*2 T cells regardless of the presence or absence of MSCs (Figures [3(c)](#fig3){ref-type="fig"}--[3(e)](#fig3){ref-type="fig"}). In contrast, coculture with UC-MSCs significantly reduced the percentages of IFN*γ*+ V*γ*9V*δ*2 T cells by 29.6% and 75.6% at cell ratios of 80 : 1 and 5 : 1 compared with the control group (*P* \< 0.05, [Figure 3(a)](#fig3){ref-type="fig"}). However, coculture with UC-MSCs significantly increased the frequency of granzyme B+ V*γ*9V*δ*2 T cells by 34.6% and 109.5% for 80 : 1 and 5 : 1 UC-MSCs compared with control group (*P* \< 0.05, [Figure 3(b)](#fig3){ref-type="fig"}). The regulatory effects of UC-MSCs trended to be dose-dependent. Hence, UC-MSCs regulated the expression of cytokines and functional enzymes in V*γ*9V*δ*2 T cells.

3.3. UC-MSCs Inhibit the Cytotoxicity of V*γ*9V*δ*2 T Cells against Influenza Virus-Infected A549 Cells {#sec3.3}
-------------------------------------------------------------------------------------------------------

Activated V*γ*9V*δ*2 T cells have cytotoxicity against influenza virus-infected A549 cells \[[@B23]\]. To determine the impact of UC-MSCs on the cytotoxicity of V*γ*9V*δ*2 T cells, the isolated PBMCs were stimulated with PAM and IL-2 for 12 days and were cocultured with, or without, irradiated UC-MSCs in triplicate at cell ratios of 5 : 1 or 80 : 1 for 60 hours. After purification of V*γ*9V*δ*2 T cells, the purified V*γ*9V*δ*2 T cells (effector) were cocultured with influenza virus- (H1N1-) infected A549 cells (target) at an effector-to-target (E/T) ratio of 10 : 1 for 5 hours. Subsequently, the cells were stained with APC-cy7-anti-CD3 and 7AAD, and after being gated on CD3-A549 cells, the percentages of dead A549 cells in total A549 cells were determined by flow cytometry ([Figure 4(a)](#fig4){ref-type="fig"}). Coculture of V*γ*9V*δ*2 T cells with UC-MSCs significantly reduced the percentages of dead A549 cells and the inhibitory effects of UC-MSCS on V*γ*9V*δ*2 T cell-mediated cytotoxicity against influenza virus-infected A549 cells trended to be dose-dependent ([Figure 4(b)](#fig4){ref-type="fig"}).

3.4. UC-MSCs Modulate the Fas-L and TRAIL Expression and Activated V*γ*9V*δ*2 T Cell Apoptosis {#sec3.4}
----------------------------------------------------------------------------------------------

Finally, we investigated the impact of UC-MSCs on the apoptosis of activated V*γ*9V*δ*2 T cells. The isolated V*γ*9V*δ*2 T cells were stimulated with PAM and IL-2 in the presence or absence of irradiated UC-MSCs at a ratio of 80 : 1 or 5 : 1 for 14 days. Subsequently, the cells were harvested and stained with APC-cy7-anti-CD3, FITC-Annexin V, and 7-AAD and the percentages of apoptotic cells were determined by flow cytometry. There was no significant difference in the percentages of apoptotic cells among these groups of V*γ*9V*δ*2 T cells ([Figure 5(a)](#fig5){ref-type="fig"}). Furthermore, some cells were stained with APC-cy7-anti-CD3, APC-anti-TCRV*γ*9V*δ*2, and PE-anti-Fas-L or PE-anti-TRAIL. The percentages of Fas-L+ or TRAIL+ V*γ*9V*δ*2 T cells were determined by flow cytometry. Quantitative analysis indicated that the percentages of Fas-L+ V*γ*9V*δ*2 T cells when cultured with UC-MSCS at 5 : 1 were significantly lower than that of V*γ*9V*δ*2 T cells without being cocultured with UC-MSCs ([Figure 5(b)](#fig5){ref-type="fig"}). Similarly, the percentages of TRAIL+ V*γ*9V*δ*2 T cells cocultured with UC-MSCs were significantly lower than that of V*γ*9V*δ*2 T cells in the absence of UC-MSCs ([Figure 5(c)](#fig5){ref-type="fig"}). Therefore, UC-MSCs inhibited Fas-L and TRAIL expression but failed to modulate the spontaneous apoptosis of activated V*γ*9V*δ*2 T cells in vitro.

4. Discussion {#sec4}
=============

MSCs have potent immunoregulatory activities and have been tested in the clinical trials for intervention of different inflammatory diseases \[[@B13]\]. UC-MSCs have more advantages than bone marrow-derived ones because of their noninvasive nature and having less immunogenicity as well as powerful proliferative capacity \[[@B2], [@B14]\]. UC-MSCs have been demonstrated to inhibit the function of *αβ* T cells \[[@B3], [@B5], [@B6]\], NK cells \[[@B3], [@B7]--[@B9]\], macrophages \[[@B3]\], and DCs \[[@B2], [@B3], [@B10]\] but positively regulate Tregs \[[@B11]\]. In this study, we examined the effect of UC-MSCs on the proliferation and cytotoxicity of V*γ*9V*δ*2 T cells as well as their cytokine and effector expression in vitro. We found that UC-MSCs inhibited the proliferation of PAM/IL-2 stimulated V*γ*9V*δ*2 T cells in a dose-dependent and cell-cell contact-independent manner. Furthermore, we found that UC-MSCs inhibited the expression of IFN*γ* but enhanced granzyme B expression in activated V*γ*9V*δ*2 T cells. In addition, UC-MSCs inhibited the cytotoxicity of activated V*γ*9V*δ*2 T cells against influenza virus-infected A549 cells. The expression of Fas-L and TRAIL on V*γ*9V*δ*2 T cells were inhibited by UC-MSCs as well. However, UC-MSCS failed to modulate the spontaneous apoptosis of activated V*γ*9V*δ*2 T cells. Previous studies have shown that bone marrow-derived MSCs inhibit effector T cell proliferation and IFN*γ* and TNF*α* expression and cytotoxicity against cancer cells \[[@B29], [@B30]\]. Our data extended previous findings and support the notion that UC-MSCs are powerful inhibitors of T cell immunity. To the best of our knowledge, this was the first report on the regulatory effects of UC-MSCs on the activation and function of human V*γ*9V*δ*2 T cells. Our novel findings may provide new insights into understanding of the regulatory mechanisms underlying the action of UC-MSCs.

In this study, we found that UC-MSCs inhibit the proliferation of PAM/IL-2 stimulated V*γ*9V*δ*2 T cell proliferation in a cell-cell contact-independent manner. While inhibition of T cell proliferation is associated with inducing T cell apoptosis. However, we did not observe that UC-MSCs significantly modulated the apoptosis of activated V*γ*9V*δ*2 T cells in vitro, which may be associated with lower levels of Fas-L and TRAIL expression in V*γ*9V*δ*2 T cells with the presence of UC-MSCs. These findings suggest that UC-MSCs may secrete soluble factors that inhibit V*γ*9V*δ*2T cell proliferation. MSCs can secrete many factors, including transforming growth factor-*β* (TGF-*β*) \[[@B31]\], hepatic growth factors (HGF) \[[@B32]\], prostaglandin E2 (PGE2) \[[@B31]\], IL-10 \[[@B31]\], indolamine 2,3-dioxygenase (IDO) \[[@B33], [@B34]\], nitric oxide (NO) \[[@B31]\], heme oxygenase-1 (HO-1) \[[@B35]\], and human leukocyte antigen-G (HLA-G) \[[@B36]\], and TGF-*β*, IL-10, and PGE2 are potent inhibitors of T cell immunity \[[@B4], [@B37]--[@B39]\]. These factors together with other unknown factors may act to inhibit T cell proliferation directly and indirectly. We are interested in further investigating what factors positively regulate granzyme B expression in V*γ*9V*δ*2 T cells.

We speculate that the interaction of UC-MSCs with V*γ*9V*δ*2 T cells may be similar to that with NK cells \[[@B40]\]. It is possible that minor allogeneic antigens on UC-MSCS may trigger IFN*γ* V*γ*9V*δ*2 T cell responses and upregulate granzyme B expression, leading to the cytotoxicity against UC-MSCs by the granzyme-NKG2D pathway. Simultaneously, inhibitory factors, such as PGE~2~ \[[@B33], [@B34]\], TGF-*β* \[[@B3]\], IDO \[[@B33], [@B34]\], NO \[[@B34]\], and IL-10 \[[@B10], [@B41]\], secreted by UC-MSCs downregulate the function of V*γ*9V*δ*2 T cells and the serine protease inhibitor 9 (SERPINB9) produced by UC-MSCs attenuates the activity of granzyme B-mediated cytotoxicity. Subsequently, inhibitory factors secreted by UC-MSCs control the function of V*γ*9V*δ*2 T cells by reducing IFN*γ*, Fas-L, and TRAIL expression in V*γ*9V*δ*2 T cells. Immunosuppressive functions of different sources of MSCs are varying and their functions are regulated by many other immunocompetent cells in vivo \[[@B42]\]. Therefore, we are interested in further investigating the precise mechanisms underlying the action of UC-MSCs in regulating the function and survival of V*γ*9V*δ*2 T cells.

Even though the mechanisms underlying the cytotoxicity of V*γ*9V*δ*2 T cells against virus infection are still incompletely understood, the protective role of V*γ*9V*δ*2 T cells has been proved in acute and chronic virus infections. Following the infection with different strains of influenza viruses, V*γ*9V*δ*2 T cells can secrete antiviral cytokines and directly kill virus-infected target cells \[[@B43]--[@B45]\], which can be enhanced by phosphoantigen stimulation \[[@B45], [@B46]\]. UC-MSCs can significantly inhibit the cytotoxicity of V*γ*9V*δ*2 T cells against HIN1 influenza virus in vitro. This result indicates that maybe in viral infection, especially in H1N1 influenza virus infection, UC-MSCs suppress the antiviral protection of V*γ*9V*δ*2 T cells. This needs to be proved in further studies.

In summary, our data indicated that human UC-MSCs inhibited the PAM/IL-2 stimulated V*γ*9V*δ*2 T cell proliferation in a cell-to-cell contact-independent manner and modulated cytokine secretion by V*γ*9V*δ*2 T cells. Furthermore, UC-MSCs inhibited the cytotoxicity of activated V*γ*9V*δ*2 T cells against influenza virus-infected A549 cells. These regulations may be mediated by the inhibition of Fas-L and TRAIL expression byV*γ*9V*δ*2 T cells but not by inducing the apoptosis of V*γ*9V*δ*2 T cells. Our novel data support that UC-MSCs can exhibit immune regulatory capacity by inhibiting V*γ*9V*δ*2 T cells and our findings may provide some clues for further research on the interaction between UC-MSCs and V*γ*9V*δ*2 T cells.
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![UC-MSCs inhibit *γδ* T cells proliferation in a dose-dependent manner. PBMCs from healthy donors were stained with CFSE (1 *μ*M) and cocultured with, or without, UC-MSCs at the indicated (T : MSCs) ratios for 14 days. The cells were stained with different fluorescent antibodies, as described in in the method section, and the percentages of proliferative *γδ* T cells were determined by flow cytometry. The cells were gated on CD3+TCR*γδ*+ cells and their proliferation was characterized by flow cytometry, followed by quantification. Data are representative charts and histograms or expressed as the means ± SEM of each group of cells from 15 healthy donors. (a) The representative population of CD3+TCR*γδ*+ cells following coculture with, or without, UC-MSCs. (b) The representative histograms of proliferative CD3+TCR*γδ*+ cells. (c) The percentages of proliferative CD3+TCR*γδ*+ cells. ^∗^ *P* \< 0.01 versus the controls without coculture with UC-MSCs. UC-MSC: umbilical cord mesenchymal stem cell; PBMC: peripheral blood mononuclear cell; CFSE: 5,6-carboxyfluorescein diacetate succinimidyl ester.](BMRI2015-317801.001){#fig1}

![UC-MSCs inhibit the proliferation of *γδ* T cells in a cell-cell contact-independent manner. PBMCs from three healthy donors were labeled with CSFE and cocultured with, or without, UC-MSCs at the different ratios in transwell or together in 6-well plates, followed by simulation with PAM and IL-2 for 14 days. Subsequently, the cells were stained with fluorescent antibodies, as described in the method section. The cells were gated on CD3+TCR*γδ*+ and the percentages of proliferative *γδ* T cells were determined by flow cytometry. Data are expressed as the mean percentages ± SEM of each group of cells from three separate experiments. (a) The percentages of proliferative *γδ* T cells following a separated coculture in transwell plates. (b) The percentages of proliferative *γδ* T cells following coculture in transwell or 24-well plates. ^∗^ *P* \< 0.01 versus the controls. UC-MSC: umbilical cord mesenchymal stem cell; PBMC: peripheral blood mononuclear cell.](BMRI2015-317801.002){#fig2}

![UC-MSCs modulate the expression of cytokines and bioactive effectors in *γδ* T cells. PBMCs were isolated and stimulated with PAM and IL-12 for 12 days. The enriched *γδ* T cells were cocultured with UC-MSCs at the indicated ratios for 48 hours and the cells were stained with different fluorescent antibodies, as described in in the method section. Subsequently, the percentages of IFN*γ*+, granzyme B+, TNF*α*+, perforin+, or IL-10+ *γδ* T cells were characterized by flow cytometry. Data are representative flow cytometry charts or expressed as the mean percentages ± SEM of each group of cells from nine subjects of nine separate experiments. (a--e) Quantitative analysis of the percentages of *γδ* T cells. ^∗^ *P* \< 0.05 versus the controls. UC-MSC: umbilical cord mesenchymal stem cell; PBMC: peripheral blood mononuclear cell; TNF*α*: tumor necrosis factor; IFN*γ*: interferon-*γ*; IL-10: interleukin-10.](BMRI2015-317801.003){#fig3}

![UC-MSCs inhibit the cytotoxicity of activated *γδ* T cells against influenza virus-infected A549 cells in vitro. PBMCs were stimulated with PAM and IL-2 for 12 days and cocultured with, or without, the different ratios of UC-MSCs for 60 hours. Subsequently, the activated *γδ* T cells were purified from the different groups of cells by FACS sorting and the purified *γδ* T cells were cocultured with influenza virus-infected A549 cells at a ratio of 10 : 1 for 5 hours and stained with APC-anti-CD3, FITC-Annexin V, and 7-AAD. The percentages of apoptotic A549 cells were characterized by flow cytometry after gating on CD3-cells. Data are representative flow cytometry charts or expressed as the mean percentages ± SEM of each group of cells from 19 subjects. (a) The representative flow cytometry charts. (b) Quantitative analysis of the percentages of apoptotic A549 cells. ^∗^ *P* \< 0.05 versus the controls. UC-MSC: umbilical cord mesenchymal stem cell.](BMRI2015-317801.004){#fig4}

![UC-MSCs modulate the expression of Fas-L and TRAIL on *γδ* T cells but do not affect the spontaneous apoptosis of activated *γδ* T cells. PBMCs were cocultured with, or without, the different ratios of UC-MSCs in the presence of PAM and IL-2 for 14 days. The cells were stained with fluorescent antibodies, as described in in the method section. The percentages of apoptotic *γδ* T cells and Fas-L+ or TRAIL+ *γδ* T cells were characterized by flow cytometry analysis. Data are representative flow cytometry analysis of the frequency of apoptotic *γδ* T cells or expressed as the mean percent ± SEM of each group of cells from 19 subjects. (a--c) The quantitative analysis of apoptosis, Fas-L, and TRAIL. ^∗^ *P* \< 0.05, ^∗∗^ *P* \< 0.05 versus the controls. UC-MSC: umbilical cord mesenchymal stem cell; PBMC: peripheral blood mononuclear cell; Fas-L: Fas ligand; Trail: tumor necrosis factor-related apoptosis-inducing ligand.](BMRI2015-317801.005){#fig5}
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